Literature DB >> 9180160

A phospholipase D and protein kinase C inhibitor blocks the spreading of murine mammary adenocarcinoma cells altering f-actin and beta1-integrin point contact distribution.

J A Aguirre Ghiso1, E F Farías, D F Alonso, C Arregui, E Bal de Kier Joffé.   

Abstract

Spreading is a critical process involved in motility and growth of tumor cells during the metastatic cascade. Focal adhesion kinase, src-proteins and PKC have been reported to participate in the regulation of cytoskeleton organization in both normal and transformed cells during spreading. The role of other signaling enzymes such as PLD and PAP has not been studied during spreading in tumor cells. We now show that the spreading of murine mammary adenocarcinoma LM3 cells was significantly reduced by n-butanol, a PLD and PKC inhibitor, with a maximal inhibition of 54% (p < 0.001) in both the presence and absence of serum, as measured by phase-contrast microscopy. PMA only stimulated cell spreading over the control in the absence of serum and n-butanol inhibition was completely reversed by PMA treatment in both conditions. PA, the product of PLD activity, stimulated LM3 cell spreading and the same effect was observed with staurosporine. Spreading was enhanced when cells were seeded on collagen-IV- or fibronectin-coated surfaces and n-butanol could inhibit both integrin-derived signals. Cell spreading inhibition correlated with the absence of f-actin bundles and fewer beta1-integrin point contacts as determined by double immunofluorescence microscopy. In addition, n-butanol inhibited the proliferation of LM3 cells in the presence of serum (p < 0.01). These results suggest that beta1-integrin and f-actin/point contact assembly, involved in spreading and proliferation, require the participation of PLD-PKC regulatory pathways in LM3 cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9180160     DOI: 10.1002/(sici)1097-0215(19970529)71:5<881::aid-ijc29>3.0.co;2-9

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  5 in total

1.  A comprehensive model that explains the regulation of phospholipase D2 activity by phosphorylation-dephosphorylation.

Authors:  Karen M Henkels; Hong-Juan Peng; Kathleen Frondorf; Julian Gomez-Cambronero
Journal:  Mol Cell Biol       Date:  2010-02-22       Impact factor: 4.272

Review 2.  Phospholipase D: molecular and cell biology of a novel gene family.

Authors:  M Liscovitch; M Czarny; G Fiucci; X Tang
Journal:  Biochem J       Date:  2000-02-01       Impact factor: 3.857

3.  A 90-kD phospholipase D from tobacco binds to microtubules and the plasma membrane.

Authors:  J C Gardiner; J D Harper; N D Weerakoon; D A Collings; S Ritchie; S Gilroy; R J Cyr; J Marc
Journal:  Plant Cell       Date:  2001-09       Impact factor: 11.277

4.  Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness.

Authors:  Sarah A Scott; Paige E Selvy; Jason R Buck; Hyekyung P Cho; Tracy L Criswell; Ashley L Thomas; Michelle D Armstrong; Carlos L Arteaga; Craig W Lindsley; H Alex Brown
Journal:  Nat Chem Biol       Date:  2009-01-11       Impact factor: 15.040

Review 5.  Phospholipase D signaling pathways and phosphatidic acid as therapeutic targets in cancer.

Authors:  Ronald C Bruntz; Craig W Lindsley; H Alex Brown
Journal:  Pharmacol Rev       Date:  2014-10       Impact factor: 25.468

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.